| Identification | Back Directory | [Name]
Nampt-IN-3 | [CAS]
2121591-52-2 | [Synonyms]
Nampt-IN-3
NamptIN3,Nampt IN 3
Benzamide, 4-[1-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-1H-1,2,3-triazol-4-yl]-N-(3-pyridinylmethyl)- | [Molecular Formula]
C29H25N7O2 | [MDL Number]
MFCD32174256 | [MOL File]
2121591-52-2.mol | [Molecular Weight]
503.55 |
| Chemical Properties | Back Directory | [density ]
1.31±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
12.84±0.46(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Nampt-IN-3 (Compound 35) simultaneously inhibit nicotinamide phosphoribosyltransferase (NAMPT) and HDAC with IC50s of 31 nM and 55 nM, respectively. Nampt-IN-3 effectively induces cell apoptosis and autophagy and ultimately leads to cell death[1]. | [storage]
Store at -20°C | [References]
[1] Dong G, et al. Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors. J Med Chem. 2017 Oct 12;60(19):7965-7983 DOI:10.1021/acs.jmedchem.7b00467 |
|
|